Prostate Cancer
Advertisement
Researchers focused on the economic impact of disparities related to insurance coverage.
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Darolutamide plus ADT provided a clinically meaningful increase in rPFS compared with placebo plus ADT.
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Abiraterone acetate, prednisone, and apalutamide is a common combination treatment for mCRPC.
The detection rate in biopsy-naïve men undergoing MRI-targeted transrectal or transperineal biopsy was 59% and 62%.
While postoperative hypofractionated radiotherapy is a common treatment, data focusing on long-term outcomes are scarce.
Patients in the oADT cohort experienced decreased cholesterol levels and increased testosterone and hemoglobin levels.
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
For the treatment of localized prostate cancer, guidelines typically recommend the addition of ADT to RT in certain patients.
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
The study’s primary end points were the incidence of all-grade or grade 3 and higher cardiovascular events.
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.